Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...

Rezera, formerly known as NodThera until a rebrand earlier this year, has announced the terms of its planned Nasdaq IPO, ...

Moderna's mRNA-1469 and ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, ...

For years, success in kidney disease has largely been measured by how much its progression could be slowed. Newer treatments ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

The one-year-old start-up is the latest to receive financial backing from the UK government's £500 million Sovereign AI ...

Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell ...

UK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in the US behind it, after agreeing a $600 million settlement. The deal resolves criminal ...

Estima co-founders Tim Reason and Andy Gimblett are joining EVERSANA. EVERSANA has acquired UK-based health economics and outcomes research (HEOR) company Estima Scientific, which develops AI and data ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...